Kelley M E, Yao J K, van Kammen D P
VA Pittsburgh Healthcare System, PA 15240, USA.
Neuropsychopharmacology. 1999 Jun;20(6):603-11. doi: 10.1016/S0893-133X(98)00094-3.
The objective of this study was to determine the association between the patterns of change in the dopaminergic metabolite plasma homovanillic acid (HVA), the noradrenergic metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), and psychosis following haloperidol withdrawal in schizophrenic patients. Weekly plasma measurements were obtained in 107 subjects with schizophrenia or schizoaffective disorder. Random regression was used to control for individual variance while modeling metabolite changes over time and relationships with psychosis. Changes in plasma MHPG were not significantly associated with relapse or psychosis, while increased plasma HVA was found to be associated with relapse. Psychosis was correlated negatively with plasma HVA levels. The current analysis, controlling for individual variance, indicates that there is evidence for pharmacological effects on plasma HVA, but not plasma MHPG. In addition, these metabolites do not appear to be direct markers of psychosis, but may be associated with a compensatory response by the system to return to the steady state.
本研究的目的是确定精神分裂症患者停用氟哌啶醇后，多巴胺能代谢物血浆高香草酸（HVA）、去甲肾上腺素能代谢物3-甲氧基-4-羟基苯乙二醇（MHPG）的变化模式与精神病之间的关联。对107例精神分裂症或分裂情感性障碍患者进行了每周一次的血浆检测。在对代谢物随时间的变化及其与精神病的关系进行建模时，采用随机回归来控制个体差异。血浆MHPG的变化与复发或精神病无显著关联，而血浆HVA升高与复发相关。精神病与血浆HVA水平呈负相关。当前的分析在控制个体差异后表明，有证据显示药物对血浆HVA有影响，但对血浆MHPG没有影响。此外，这些代谢物似乎不是精神病的直接标志物，但可能与系统恢复稳态的代偿反应有关。
